CuretraxAllo

CuretraxAllo provides treatment-specific support to Care Teams and patients who have undergone allogeneic hematopoietic stem cell transplantation (alloHSCT).

It is well known that there are unique challenges for patients and Care Teams post-alloHSCT. Some prominent challenges include the development of graft-versus-host disease (GvHD), susceptibility to infections and the potential for rapid changes in patient health and wellbeing.

To address these challenges, CuretraxAllo provides a platform for Care Teams to securely monitor the health and well-being of their patients 24/7 in real-time.

With CuretraxAllo, we aim to reduce the lengthy hospital stay of patients post-alloHSCT, ultimately allowing patients to recover in their more comfortable home environment while freeing much-needed hospital beds and other hospital resources.